ArticleBiomedicines2022

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.

Toyohiro Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.